XTL Biopharmaceuticals Ltd.

NASDAQ:XTLB

$1.88 USD

$0.03 (1.62%)

Volume
3.52K
Average Volume
40.53K
Market Capitalization
$22.78M
P/E Ratio
-103.39
Dividend Yield
0.00%
Price Target
$
Year High
$4.99
Year Low
$0.76
Payout Ratio
$0.00
Current Ratio
$11.43

Industry, Sector & symbol

Stock Exchange NASDAQ Capital Market
CEO Mr. Itay Weinstein CPA
Industry Biotechnology
Sector Healthcare
Current Symbol XTLB
CUSIP 98386D307
CIK 0001023549
Web https://www.xtlbio.com
Phone 972 3 611 6600
Currency USD
Employees 8
Country IL

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 11.43
Quick Ratio 11.43
Cash Ratio 4.79

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow 0.00
Price / Cash Flow 0.00
Price / Book 3.60

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Neutral
Rating Score(0-5) 3
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.0033
Trailing P/E Ratio -103.39
PEG Ratio -1.11
P/E Growth -1.11
Net Income $-1.78M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity -3.72%
Return on Assets -3.22%

Financials Score

AltmanZ Score -14.24
Piotroski Score 2.00
Working Capital 2.32M
Total Assets 2.93M
Ebit -926.5K
Market Cap 22.78M
Total Liabilities 223K

Poll Results

About XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Stock

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. ...

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

2024-08-14 09:15:00

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company  developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5 Million   RAMAT GAN, ISRAEL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- August 14, 2024, XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today it has completed the acquisition of THE SOCIAL PROXY Ltd.

XTL Entered Definitive Agreement to Acquire The Social Proxy

2024-06-05 09:15:00

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company  developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, June 05, 2024 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the “Company” or  “XTL”) announced today it has entered into a definitive share purchase agreement with the current shareholders of THE SOCIAL PROXY Ltd.

XTL To Aquire The Social Proxy

2024-03-20 10:15:00

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, March 20, 2024 (GLOBE NEWSWIRE) --  XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today that it has entered into a binding term sheet with THE SOCIAL PROXY Ltd.

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

2023-10-20 16:00:00

Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or SLE, and Sjögren's syndrome, or SS, today announced that the Company received a written notification (the "Notice") from the Nasdaq Stock Market LLC (“Nasdaq”) on October 18, 2023, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Rules for continued listing on the Nasdaq.

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

2023-10-20 16:00:00

Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or SLE, and Sjögren's syndrome, or SS, today addressed the status of the Company's continued and uninterrupted activity in Israel against the background of the recent severe terrorist attack in the south of the country and the subsequent declaration of war by the Israeli government against the Hamas terrorist organization.

Frequently Asked Questions

What is the current XTL Biopharmaceuticals Ltd. (XTLB) stock price?

XTL Biopharmaceuticals Ltd.(NASDAQ:XTLB) stock price is $1.88 in the last trading session. During the trading session, XTLB stock reached the peak price of $4.99 while $0.76 was the lowest point it dropped to. The percentage change in XTLB stock occurred in the recent session was 1.62% while the dollar amount for the price change in XTLB stock was $0.03.

XTLB's industry and sector of operation?

The NASDAQ listed XTLB is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of XTLB?

Mr. Itay Weinstein CPA | Chief Financial Officer
|
|
|
|

How many employees does XTLB have?

Number of XTLB employees currently stands at 8. XTLB operates from 5 Badner Street, Ramat Gan, None 5218102, IL.

Link for XTLB official website?

Official Website of XTLB is: https://www.xtlbio.com

How do I contact XTLB?

XTLB could be contacted at phone #972 3 611 6600 and can also be accessed through its website. XTLB operates from 5 Badner Street, Ramat Gan, None 5218102, IL.

How many shares of XTLB are traded daily?

The average number of XTLB shares traded daily for last 3 months was 40.53K.

What is the market cap of XTLB currently?

The market value of XTLB currently stands at $22.78M with its latest stock price at $1.88